These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

70 related articles for article (PubMed ID: 754480)

  • 1. The role of potassium-canrenoate on 3H-noradrenaline uptake and metabolism of the rat heart.
    Préda I; Sebeszta M; Harsányi A; Szabó G; Antalóczy Z
    Acta Physiol Acad Sci Hung; 1978; 51(4):393-9. PubMed ID: 754480
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The role of potassium-canrenoate in the 3H-noradrenaline uptake and metabolism of the rat heart.
    Préda I; Sebeszta M; Antalóczy Z
    Arzneimittelforschung; 1980; 30(3):436-8. PubMed ID: 7387752
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The effect of potassium canrenoate (Aldactone) on the norepinephrine metabolism and potassium ionic currents of the heart.
    Antalóczy Z; Sebeszta M; Préda I
    Adv Myocardiol; 1982; 3():215-22. PubMed ID: 6302766
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Canrenoate--a spironolactone metabolite. Acute cardiac effects in digitalized patients.
    Waldorff S; Buch J
    Eur J Cardiol; 1979 Aug; 10(2):143-9. PubMed ID: 477703
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Aldosterone antagonists in coronary insufficiency].
    Osswald H
    Med Klin; 1978 Jan; 73(3):84-8. PubMed ID: 622061
    [No Abstract]   [Full Text] [Related]  

  • 6. Canrenone as a partial agonist at the digitalis receptor site of sodium-potassium-activated adenosine triphosphatase.
    Finotti P; Palatini P
    J Pharmacol Exp Ther; 1981 Jun; 217(3):784-90. PubMed ID: 6262496
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Plasma digoxin radioimmunoassay in patients treated with potassium canrenoate and spironolactone. A comparison of two commerical kits.
    Cristodorescu R; Gavrilescu S; Deutsch G; Berger E
    Agressologie; 1978; 19(6):409-14. PubMed ID: 751526
    [No Abstract]   [Full Text] [Related]  

  • 8. [Influence of canrenoate potassium (aldactone pro injections) on hemodynamics and myocardial ischemia in experimental myocardial infarct].
    Kötter V; Leitner Ev; Arbeiter G; Cordes R; Schröder R
    Z Kardiol; 1975 Jul; 64(7):672-86. PubMed ID: 1163092
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Positive inotropic effect of K-canrenoate: an investigation in anaesthetized dogs, untreated or treated with digitalis.
    Marchetti G; Vitolo E; Di Francesco GF; Cavallaro B; Sponzilli C
    Arch Int Pharmacodyn Ther; 1983 Dec; 266(2):250-63. PubMed ID: 6667069
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Changes in lymphocytes caused by aldosterone and a spironolactone derivative. Animal experiments and clinical studies].
    Liebich HG; Mertin J; Seifert J
    Fortschr Med; 1982 Nov; 100(41):1922-5. PubMed ID: 7152425
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Response to nor-epinephrine, isoprenaline and spironolactone derivatives in normal and hypertensive rats.
    Eandi M; Ricci Gamalero S; Miocchi D
    Boll Soc Ital Biol Sper; 1979 Jul; 55(13):1252-8. PubMed ID: 508422
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Spirolactones: clinical and pharmacologic studies.
    Corvol P; Claire M; Rafestin-Oblin ME; Michaud A; Roth-Meyer C; Menard J
    Adv Nephrol Necker Hosp; 1977; 7():199-215. PubMed ID: 208407
    [No Abstract]   [Full Text] [Related]  

  • 13. Potassium prorenoate: a new steroidal aldosterone antagonist.
    Hofmann LM; Chinn LJ; Pedrera HA; Krupnick MI; Suleymanov OD
    J Pharmacol Exp Ther; 1975 Aug; 194(2):450-6. PubMed ID: 1151770
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The effect of oral spironolactone and intravenous canrenoate-K on the digoxin radioimmunoassay.
    Lichey J; Schröder R; Rietbrock N
    Int J Clin Pharmacol Biopharm; 1977 Dec; 15(12):557-9. PubMed ID: 598949
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Influence of canrenoate-K and cardiac glycosides on their tissue distribution and elimination.
    Kuhlmann J; Kötter V; Vöhringer HF; Rietbrock N; Schröder R
    Arzneimittelforschung; 1977 Jul; 27(7):1505-9. PubMed ID: 578485
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Study of the inotropic effect of potassium canrenoate by determining systolic time intervals].
    Vitolo E; Gambini E; Larovere MT; Rusconi F; Vitali GM
    Boll Soc Ital Cardiol; 1979; 24(7):775-7. PubMed ID: 554665
    [No Abstract]   [Full Text] [Related]  

  • 17. Comparative clinical study of spironolactone and potassium canrenoate. A randomized evaluation with double cross-over.
    Emili M; Cuppone R; Ricci GL
    Arzneimittelforschung; 1988 Oct; 38(10):1492-5. PubMed ID: 3058132
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Sexual side-effects of spironolactones. Possible mechanisms of their anti-androgen action].
    Corvol P; Mahoudeau JA; Valcke JC; Ménard J; Bricaire H
    Nouv Presse Med; 1976 Mar; 5(11):691-4. PubMed ID: 177946
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Myocardial potassium balance during adrenergic stimulation.
    Ellingsen O
    J Oslo City Hosp; 1989; 39(4-5):39-51. PubMed ID: 2547922
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Clinical study of the efficacy of oral potassium canrenoate and spironolactone in essential arterial hypertension].
    Tosti-Croce C; Mantellini R; Fanti P; Sciarra F
    Minerva Med; 1983 Apr; 74(14-15):791-7. PubMed ID: 6339999
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.